A detailed history of Corton Capital Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Corton Capital Inc. holds 15,805 shares of VRDN stock, worth $300,769. This represents 0.18% of its overall portfolio holdings.

Number of Shares
15,805
Previous 31,732 50.19%
Holding current value
$300,769
Previous $412,000 12.86%
% of portfolio
0.18%
Previous 0.23%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.16 - $23.33 $193,672 - $371,576
-15,927 Reduced 50.19%
15,805 $359,000
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $146,879 - $218,546
12,662 Added 66.4%
31,732 $412,000
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $9,587 - $13,363
561 Added 3.03%
19,070 $333,000
Q4 2023

Feb 14, 2024

BUY
$11.12 - $22.5 $205,820 - $416,452
18,509 New
18,509 $403,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $759M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Corton Capital Inc. Portfolio

Follow Corton Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Corton Capital Inc. with notifications on news.